NTHI’s Nasdaq Advantage Takes on New Meaning After Its Breakthrough Phase 2a Results
NeOnc Technologies Holdings (NASDAQ: NTHI) announced promising Phase 2a clinical trial results for its drug candidate NEO100 in treating recurrent IDH1-mutant high-grade glioma, including a six-month progression-free survival rate of 48.9%, significantly surpassing the historical benchmark. This clinical milestone, coupled with NTHI's Nasdaq listin…